Entering text into the input field will update the search result below

BridgeBio potential kidney stone therapy shows promise in healthy people in trial

Jun. 27, 2022 8:53 AM ETBridgeBio Pharma, Inc. (BBIO) StockBy: Ravikash Bakolia, SA News Editor

Kidney disease concept. Viral infection. 3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

BridgeBio Pharma (NASDAQ:BBIO) said positive phase 1 data of BBP-711 in healthy volunteers supports developing the therapy for patients with primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formers.

PH1 is a

Recommended For You

More Trending News

About BBIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BBIO--
BridgeBio Pharma, Inc.